Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Phibro Animal Health (PAHC) EBITDA Margin (2016 - 2026)

Phibro Animal Health has reported EBITDA Margin over the past 14 years, most recently at 13.46% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1574.0% year-over-year to 13.46%; the TTM value through Dec 2025 reached 10.11%, up 669.0%, while the annual FY2025 figure was 8.52%, 328.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 13.46% at Phibro Animal Health, up from 8.39% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 13.46% in Q4 2025 and troughed at 2.28% in Q4 2024.
  • A 5-year average of 5.85% and a median of 7.56% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: crashed -756bps in 2021 and later soared 1574bps in 2025.
  • Year by year, EBITDA Margin stood at 4.66% in 2021, then decreased by -8bps to 4.28% in 2022, then crashed by -76bps to 1.01% in 2023, then crashed by -326bps to 2.28% in 2024, then soared by 691bps to 13.46% in 2025.
  • Business Quant data shows EBITDA Margin for PAHC at 13.46% in Q4 2025, 8.39% in Q3 2025, and 8.9% in Q2 2025.